Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Differences in synthesis and absorption of cholesterol of two effective lipid-lowering therapies

Full text
Kasmas, S. H. [1] ; Izar, M. C. [1, 2] ; Franca, C. N. [1] ; Ramos, S. C. [1] ; Moreira, F. T. [1] ; Helfenstein, T. [1, 2] ; Moreno, R. A. [3] ; Borges, N. C. [3] ; Figueiredo-Neto, A. M. [2] ; Fonseca, F. A. [1, 2]
Total Authors: 10
[1] Univ Fed Sao Paulo, Div Cardiol, Dept Med, BR-04039030 Sao Paulo - Brazil
[2] Inst Nacl Ciencia & Tecnol Fluidos Complexos, Sao Paulo - Brazil
[3] Synchrophar, Campinas, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Brazilian Journal of Medical and Biological Research; v. 45, n. 11, p. 1095-1101, NOV 2012.
Web of Science Citations: 9

Effective statin therapy is associated with a marked reduction of cardiovascular events. However, the explanation for full benefits obtained for LDL cholesterol targets by combined lipid-lowering therapy is controversial. Our study compared the effects of two equally effective lipid-lowering strategies on markers of cholesterol synthesis and absorption. A prospective, open label, randomized, parallel design study, with blinded endpoints, included 116 subjects. We compared the effects of a 12-week treatment with 40 mg rosuvastatin or the combination of 40 mg simvastatin/10 mg ezetimibe on markers of cholesterol absorption (campesterol and beta-sitosterol), synthesis (desmosterol), and their ratios to cholesterol. Both therapies similarly decreased total and LDL cholesterol, triglycerides and apolipoprotein B, and increased apolipoprotein A1 (P < 0.05 vs baseline for all). Simvastatin/ezetimibe increased plasma desmosterol (P = 0.012 vs baseline), and decreased campesterol and beta-sitosterol (P < 0.0001 vs baseline for both), with higher desmosterol (P = 0.007) and lower campesterol and beta-sitosterol compared to rosuvastatin, (P < 0.0001, for both). In addition, rosuvastatin increased the ratios of these markers to cholesterol (P < 0.002 vs baseline for all), whereas simvastatin/ezetimibe significantly decreased the campesterol/cholesterol ratio (P = 0.008 vs baseline) and tripled the desmosterol/cholesterol ratio (P < 0.0001 vs baseline). The campesterol/cholesterol and beta-sitosterol/cholesterol ratios were lower, whereas the desmosterol/cholesterol ratio was higher in patients receiving simvastatin/ezetimibe (P < 0.0001 vs rosuvastatin, for all). Pronounced differences in markers of cholesterol absorption and synthesis were observed between two equally effective lipid-lowering strategies. (AU)

FAPESP's process: 08/57685-7 - NICT of Complex Fluids (IFCx)
Grantee:Antonio Martins Figueiredo Neto
Support type: Research Projects - Thematic Grants